MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
25 sept. 2024 03h00 HE | Medigene AG
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
29 août 2024 05h00 HE | Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
02 mai 2024 04h30 HE | Medigene AG
Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...